China NT Pharma Group Co., Ltd. AI Stock Analysis
Want to see HK:1011 full AI Analyst Report?
China NT Pharma Group Co., Ltd. (1011) AI Stock Analysis
China NT Pharma Group Co., Ltd.
(HKEX:1011)
Severe financial weakness is the primary drag, driven by deepening losses, negative equity, high debt, and cash burn. Bearish technical trends and a negative P/E provide additional downside signals, resulting in a very weak overall score.
China NT Pharma Group Co., Ltd. (1011) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 346.74M
- Dividend Yield
- ―
- Average Volume (3M)
- 409.96K
- Price to Earnings (P/E)
- -4.6
- Beta (1Y)
- 1.10
- Revenue Growth
- 100.34%
- EPS Growth
- 83.97%
- Country
- Hong Kong
- Employees
- 32
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
China NT Pharma Group Co., Ltd. Business Overview & Revenue Model
Company Description
China NT Pharma Group Company Limited, operating alongside its various subsidiaries, is dedicated to the full spectrum of pharmaceutical activities. This encompasses the research, development, manufacturing, commercialization, and distribution of med...
How the Company Makes Money
The company primarily makes money by selling pharmaceutical products. Revenue is generally generated through (1) sales of proprietary/branded drugs and other drug products that the company manufactures and/or commercializes, recognized when products...
China NT Pharma Group Co., Ltd. Financial Statement Overview
Summary
Revenue grew 26% in 2025 and gross margin improved, but persistent heavy losses, -274M negative equity, 317M debt, and negative operating cash flow indicate severe profitability, solvency, and cash-burn risks.
Income Statement
22NegativeBalance Sheet
12Very NegativeCash Flow
28Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 35.50M | 24.16M | 37.96M | 7.37M | 207.09M | 226.70M |
| Gross Profit | 5.84M | 9.61M | 5.26M | 7.37M | 125.29M | 145.46M |
| EBITDA | -12.90M | -11.72M | -12.57M | 1.33M | 10.39M | -17.78M |
| Net Income | -27.31M | -26.04M | -53.36M | -143.59M | -66.41M | -149.54M |
Balance Sheet | ||||||
| Total Assets | 642.73M | 347.50M | 334.07M | 329.12M | 1.01B | 955.36M |
| Cash, Cash Equivalents and Short-Term Investments | 11.91M | 7.22M | 9.62M | 1.52M | 5.93M | 9.44M |
| Total Debt | 334.93M | 316.83M | 375.95M | 344.94M | 826.45M | 832.11M |
| Total Liabilities | 694.02M | 621.45M | 733.18M | 668.69M | 1.25B | 1.17B |
| Stockholders Equity | -111.24M | -273.74M | -399.11M | -339.56M | -241.66M | -211.38M |
Cash Flow | ||||||
| Free Cash Flow | -19.82M | -24.71M | -9.24M | 37.58M | 31.72M | -135.42M |
| Operating Cash Flow | -19.66M | -24.55M | -9.07M | 50.48M | 36.21M | -134.78M |
| Investing Cash Flow | -581.88K | -154.88K | -189.00K | -22.14M | 4.53M | 257.81M |
| Financing Cash Flow | 29.46M | 24.05M | 12.65M | -28.97M | -46.68M | -124.80M |
China NT Pharma Group Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1011, the sentiment is Negative. The current price of 0.19 is below the 20-day moving average (MA) of 0.24, below the 50-day MA of 0.33, and below the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 29.58 is Positive, neither overbought nor oversold. The STOCH value of 27.16 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1011.
China NT Pharma Group Co., Ltd. Peers Comparison
Overall Rating
HK:023986Outperform
HK:287781Outperform
HK:234874Outperform
HK:089758.6Neutral
HK:149841Neutral- HK:101138Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:0239 | 86Outperform | HKD 738.59M | 7.41 | 13.59% | 8.44% | 10.63% | 39.44% |
| HK:2877 | 81Outperform | HKD 5.74B | 6.15 | 9.81% | 16.46% | -17.74% | 1.12% |
| HK:2348 | 74Outperform | HKD 1.36B | 5.01 | 6.78% | 7.00% | 6.55% | 36.62% |
| HK:0897 | 59Neutral | HKD 406.75M | 101.39 | 0.34% | ― | -8.30% | -44.44% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:1498 | 41Neutral | HKD 117.69M | -3.87 | -21.66% | ― | -6.71% | 43.14% |
| HK:1011 | 38Underperform | HKD 346.74M | -4.61 | 14.19% | ― | 100.34% | 83.97% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:1011 | China NT Pharma Group Co., Ltd. | 0.19 | -0.62 | -76.17% | |
| HK:0897 | Wai Yuen Tong Medicine Holdings Limited | 0.36 | -0.09 | -18.89% | |
| HK:1498 | PuraPharm Corp. Ltd. | 0.22 | -0.16 | -42.11% | |
| HK:2348 | Dawnrays Pharmaceutical Holdings Ltd. | 0.90 | -0.20 | -18.26% | |
| HK:0239 | Pak Fah Yeow International Limited | 2.37 | 0.11 | 5.05% | |
| HK:2877 | China Shineway Pharmaceutical Group Limited | 7.59 | 0.90 | 13.51% |
China NT Pharma Group Co., Ltd. Corporate Events
China NT Pharma Shareholders Approve New Auditor
China NT Pharma Group Co., Ltd. is a Hong Kong-listed pharmaceutical company. The release does not specify its primary products, services or market focus.Shareholders unanimously approved the appointment of HLB Hodgson Impey Cheng Limited as the comp...
China NT Pharma Challenges RMB92m Arbitral Award and Seeks Exit from Beijing Kangchen Stake
China NT Pharma Group has disclosed new legal moves tied to its Miacalcic asset transaction with Beijing Konruns Pharmaceutical and its minority stake in Beijing Kangchen Biological Technology. NT Pharma Pacific currently owns around 25.3% of Beijing...
China NT Pharma boosts capital structure as it pivots to AI-led bone health platform
China NT Pharma Group Company Limited is reshaping its healthcare and pharmaceutical business around an AI-driven health management platform for bone health, combining testing, treatment and rehabilitation to create a more integrated industry chain....
China NT Pharma weighs disposal of major Beijing Kangchen stake to fund high-tech pivot
China NT Pharma Group has disclosed supplemental information on its significant investment holdings, revealing that as of 31 December 2025 its financial assets at fair value through profit or loss totaled about RMB331 million. This amount, representi...
China NT Pharma Calls Extraordinary Meeting to Appoint New Auditor
China NT Pharma Group has called an extraordinary general meeting in Hong Kong on 9 November 2026 for shareholders to vote on the appointment of HLB Hodgson Impey Cheng Limited as the company’s new auditor. The mandate, if approved, will run until th...
China NT Pharma Pursues Court Enforcement in Shareholder Information Dispute Over Kangchen Biological
China NT Pharma says its subsidiary NT Pharma Pacific has been blocked from exercising shareholder information and governance rights at Beijing Kangchen Biological by the Konruns-related shareholders after performance guarantees tied to the Miacalcic...
China NT Pharma Faces RMB75 Million Arbitration Award Over Miacalcic Deal
China NT Pharma Group has disclosed that it received an arbitral award from the China International Economic and Trade Arbitration Commission related to a 2020 Miacalcic assets transaction with Beijing Konruns Pharmaceutical. The dispute concerns def...
China NT Pharma Names HLB as New Auditor After Shareholder Rebuff
China NT Pharma Group Co., Ltd., a Cayman Islands-incorporated pharmaceutical group listed in Hong Kong, focuses on developing and distributing medicines in the Chinese healthcare market through its subsidiaries. The company’s adherence to Hong Kong...
China NT Pharma Completes Loan Capitalisation Via Major Share Subscription
China NT Pharma Group has completed a connected transaction to capitalise outstanding loans through the subscription of new shares under a specific mandate. On 4 September 2026, the company issued 847,565,892 new shares at HK$0.365 each, with the con...
China NT Pharma Overhauls Key Company Secretary and Compliance Roles
China NT Pharma Group has announced the resignation of company secretary and authorised representative Ms. Li Yifang, who also served as the firm’s Hong Kong process agent, effective 31 August 2026. The board noted that Ms. Li leaves without disagree...
China NT Pharma Wins Share Issue Mandate but Loses Auditor Vote at EGM
Shareholders of China NT Pharma Group Co., Ltd. met in an extraordinary general meeting in Hong Kong on 28 August 2026 to vote on financing and governance matters. Certain interested shareholders, including subscribers to new share issues and parties...
NT Pharma Revenue Nearly Doubles but Interim Losses Persist
China NT Pharma Group Co., Ltd., listed in Hong Kong and incorporated in the Cayman Islands, operates as a pharmaceutical and healthcare services group in mainland China. Its revenue is derived from service-based offerings, positioning the company wi...
China NT Pharma Faces RMB92 Million Arbitration Award Over 2020 Asset Deal
China NT Pharma Group Company Limited has received an arbitration award from the China International Economic and Trade Arbitration Commission related to guarantee arrangements under a 2020 asset transaction with Beijing Konruns Pharmaceutical. The d...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026